首页 工具
登录
购物车
Raltegravir potassium

Raltegravir potassium

产品编号 T2239   CAS 871038-72-1
别名: MK 0518 potassium salt, Raltegravir potassium salt, 雷特格韦钾盐

Raltegravir potassium (MK 0518 potassium salt) 是一种整合酶抑制剂,用于研究 HIV 感染。

TargetMol的所有产品和服务仅用于科学研究,不能被用于人体,我们也不向个人提供产品和服务。
Raltegravir potassium Chemical Structure
Raltegravir potassium, CAS 871038-72-1
规格 价格/CNY 货期 数量
5 mg ¥ 247 现货
10 mg ¥ 372 现货
25 mg ¥ 652 现货
50 mg ¥ 1,080 现货
100 mg ¥ 1,830 现货
200 mg ¥ 2,720 现货
500 mg ¥ 4,380 现货
1 mL * 10 mM (in DMSO) ¥ 263 现货
其他形式的 Raltegravir potassium:
千万补贴 助力科研
BCA蛋白浓度测定试剂盒限时半价
Venetoclax限时半价
产品目录号及名称: Raltegravir potassium (T2239)
点击图片重新获取验证码
选择批次  
纯度: 99.45%
纯度: 98%
更多批次查询请联系客服
生物活性
化学信息
存储 & 溶解度
参考文献
产品描述 Raltegravir potassium (MK 0518 potassium salt) salt(MK0518 potassium salt) is a potent integrase (IN) inhibitor, used to treat HIV infection.
体外活性 PFV IN carrying the S217H substitution is 10-fold less susceptible to Raltegravir with IC50 of 900 nM. PFV IN displays 10% of WT activity and is inhibited by Raltegravir with an IC50 of 200 nM which indicates an appr twofold decrease in susceptibility to the IN strand transfer inhibitor (INSTI) compared with WT IN. S217Q PFV IN is as sensitive to Raltegravir as the WT enzyme[1]. Raltegravir is metabolized by glucuronidation, not hepatically. Raltegravir has potent in vitro activity against HIV-1, with a 95% inhibitory concentration of 31±20 nM, in human T lymphoid cell cultures. Raltegravir is also active against HIV-2 when Raltegravir is tested in CEMx174 cells, with an IC95 of 6 nM. Raltegravir metabolism occurs primarily through glucuronidation. Drugs that are strong inducers of the glucuronidation enzyme, UGT1A1, significantly reduce Raltegravir concentrations and should not be used. Raltegravir exhibits weak inhibitory effects on hepatic cytochrome P450 activity. Raltegravir does not induce CYP3A4 RNA expression or CYP3A4-dependent testosterone 6-β-hydroxylase activity[2]. Raltegravir cellular permeativity is reduced in the presence of magnesium and calcium[3]. Raltegravir and related HIV-1 integrase (IN) strand transfer inhibitors (INSTIs efficiently block viral replication[4]. SIVmac251 replication is efficiently inhibited by Raltegravir, which shows an EC90 in the low nanomolar range in acutely infected human lymphoid CD4+ T-cell lines MT-4 and CEMx174[5].
体内活性 Raltegravir induces viro-immunological improvement of nonhuman primates with progressing SIVmac251 infection. One non-human primate exhibits an undetectable viral load following Raltegravir monotherapy[5].
细胞实验 Human MT-4 cells are infected for 2 hours with the SIVmac251, HIV-1 (IIIB) and HIV-2 (CDC 77618) stocks at a multiplicity of infection of, approximately, 0.1. Cells are then washed three times in phosphate buffered saline, and suspended at 5 × 105/mL in fresh culture medium (to primary cells 50 units/mL of IL-2 are added) in 96-well plates, in the presence or absence of a range of triplicate raltegravir concentrations (0.0001 μM-1 μM). Untreated infected and mock-infected controls are prepared too, in order to allow comparison of the data derived from the different treatments. Viral cytopathogeniciy in MT-4 cells is quantitated by the methyl tetrazolium (MTT) method (MT-4/MTT assay) when extensive cell death in control virus-infected cell cultures is detectable microscopically as lack of capacity to re-cluster. The capability of MT-4 cells to form clusters after infection. Briefly, clusters are disrupted by pipetting; and, after 2 hours of incubation at 37°C, the formation of new clusters is assessed by light microscopy (100× magnification). Cell culture supernatants are collected for HIV-1 p24 and HIV-2/SIVmac251 p27 core antigen measurement by ELISA. In CEMx174-infected cell cultures, which show a propensity to form syncytia induced by the virus envelope glycoproteins, syncytia are counted, in blinded fashion, by light microscopy for each well at 5 days following infection.
别名 MK 0518 potassium salt, Raltegravir potassium salt, 雷特格韦钾盐
分子量 482.51
分子式 C20H20FN6O5·K
CAS No. 871038-72-1

存储

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度

DMSO: 87 mg/mL(180.3 mM)

溶液配制表

可选溶剂 浓度 体积 质量 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.0725 mL 10.3625 mL 20.725 mL 51.8124 mL
5 mM 0.4145 mL 2.0725 mL 4.145 mL 10.3625 mL
10 mM 0.2072 mL 1.0362 mL 2.0725 mL 5.1812 mL
20 mM 0.1036 mL 0.5181 mL 1.0362 mL 2.5906 mL
50 mM 0.0414 mL 0.2072 mL 0.4145 mL 1.0362 mL
100 mM 0.0207 mL 0.1036 mL 0.2072 mL 0.5181 mL

TargetMol Calculator计算器

摩尔浓度计算器
稀释计算器
配液计算器
分子量计算器
=
X
X
X
=
X
=
/
g/mol

输入分子式,点击计算,可计算出产品的分子量。

TargetMol Library Books参考文献

1. Hare, S., et al., Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proc Natl Acad Sci U S A, 2010. 107(46): p. 20057-62. 2. Hicks C, et al. Raltegravir: the first HIV type 1 integrase inhibitor. Clin Infect Dis. 2009 Apr 1;48(7):931-9. 3. Moss DM, et al. Divalent metals and pH alter raltegravir disposition in vitro. Antimicrob Agents Chemother. 2012 Jun;56(6):3020-6. 4. Hare S, et al. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol. 2011 Oct;80(4):565-72. 5. Lewis, M.G., et al. Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy. Retrovirology, 2010. 7: p. 21.
Jacoumaric acid PF-3450074 Ritonavir Kaempferol Methyl salvionolate A HIV-1 Nef-IN-1 Nelfinavir Mesylate Valepotriate

相关化合物库

该产品包含在如下化合物库中:
抑制剂库 EMA 上市药物库 药物功能重定位化合物库 高选择性抑制剂库 儿童药物库 FDA 上市药物库 经典已知活性库 上市药物库 NO PAINS 化合物库 免疫/炎症分子化合物库

TargetMol Calculator剂量换算

对于不同动物的给药剂量换算,您也可以参考 更多...

TargetMol Calculator 体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。

第一步:请输入动物实验的基本信息
剂量
mg/kg
每只动物体重
g
给药体积
μL
动物数量
第二步:请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
% Tween 80
% ddH2O
计算 重置

技术支持

您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。

Keywords

Raltegravir potassium 871038-72-1 Microbiology/Virology Proteases/Proteasome HIV Protease Integrase Raltegravir inhibit HIV Inhibitor MK 0518 MK 0518 potassium salt Human immunodeficiency virus Raltegravir potassium salt MK-0518 MK0518 HIV Integrase 雷特格韦钾盐 MK 0518 potassium inhibitor

 

TargetMol Loading
陶术
生物
TargetMol®中国区唯一合作伙伴
点击进入陶术生物官网陶术生物
联系我们
400-820-0310

上海市静安区江场三路238号8楼